About Coherus Oncology, Inc.
https://www.coherus.comCoherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States.
CEO
Dennis M. Lanfear
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 63
Ratings Snapshot
Rating : A
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:11.75M
Value:$18.8M
BLACKROCK, INC.
Shares:10.46M
Value:$16.74M
VANGUARD GROUP INC
Shares:10.32M
Value:$16.51M
Summary
Showing Top 3 of 164
About Coherus Oncology, Inc.
https://www.coherus.comCoherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $11.57M ▲ | $52.18M ▼ | $-35.53M ▼ | -307.07% ▼ | $-0.31 ▲ | $-41.23M ▲ |
| Q2-2025 | $10.25M ▲ | $52.34M ▲ | $297.77M ▲ | 2.9K% ▲ | $-0.36 ▲ | $-41.57M ▲ |
| Q1-2025 | $7.6M ▼ | $50.38M ▼ | $-56.57M ▼ | -744.43% ▼ | $-0.49 ▼ | $-44.2M ▲ |
| Q4-2024 | $54.14M ▼ | $62.53M ▲ | $-50.7M ▼ | -93.63% ▼ | $-0.44 ▼ | $-44.32M ▼ |
| Q3-2024 | $70.77M | $56.42M | $-10.75M | -15.19% | $-0.09 | $-3.84M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $191.66M ▼ | $516.52M ▲ | $428.75M ▲ | $87.77M ▼ |
| Q2-2025 | $237.64M ▲ | $439.46M ▲ | $319.64M ▼ | $119.83M ▲ |
| Q1-2025 | $82.41M ▼ | $371.07M ▼ | $554.54M ▼ | $-183.47M ▼ |
| Q4-2024 | $125.99M ▲ | $448.53M ▼ | $580.52M ▼ | $-131.99M ▼ |
| Q3-2024 | $97.69M | $505M | $592.97M | $-87.97M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-35.53M ▼ | $-46.34M ▲ | $-67.23M ▼ | $2K ▲ | $-113.56M ▼ | $-46.34M ▲ |
| Q2-2025 | $297.77M ▲ | $-46.63M ▼ | $462.64M ▲ | $-281.52M ▼ | $134.48M ▲ | $-46.63M ▼ |
| Q1-2025 | $-56.57M ▼ | $-25.83M ▼ | $-17.49M ▼ | $-264K ▼ | $-43.58M ▼ | $-25.83M ▼ |
| Q4-2024 | $-50.7M ▼ | $28.61M ▲ | $-542K ▼ | $231K ▲ | $28.3M ▲ | $28.61M ▲ |
| Q3-2024 | $-10.75M | $-62.02M | $444K | $-167K | $-61.74M | $-62.02M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Product and Service Other | $10.00M ▲ | $0 ▼ | $0 ▲ | $0 ▲ |
 Product | $190.00M ▲ | $0 ▼ | $0 ▲ | $0 ▲ |
Revenue by Geography
| Region | Q3-2016 | Q3-2017 | Q2-2017 | Q1-2017 |
|---|---|---|---|---|
 NonUS | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 UNITED STATES | $160.00M ▲ | $0 ▼ | $0 ▲ | $0 ▲ |
CEO
Dennis M. Lanfear
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 63
Ratings Snapshot
Rating : A
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:11.75M
Value:$18.8M
BLACKROCK, INC.
Shares:10.46M
Value:$16.74M
VANGUARD GROUP INC
Shares:10.32M
Value:$16.51M
Summary
Showing Top 3 of 164